Abstract
In the past 5 or 10 years spectacular advances have been made in the sciences of microbiology and immunology, with the advent of gene cloning and the production of monoclonal antibodies. These developments are presenting questions to toxicologists and regulators: “Is there a range of contaminants of which toxicol-ogists and regulators should be aware?”; “Do the end products from such techniques have any common and unique toxicological properties?”
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Buchanan RE, Gibbons NE (1974) Bergey’s manual of determinative bacteriology. Williams and Wilkins, Baltimore
Department of Health and Social Security (1982) Compendium of licensing requirements for the manufacture of certain biological medicinal products. Her Majesty’s Stationery Office, London
Espeseth DA, Shibley GP, Joseph PL, van Deusen RA, Whetstone CA (1983) United States Department of Agriculture licensing policy for biologicals produced by r-DNA. Presented at Joint LABS/ WHO meeting, 18th Congress on Standardisation and control of biologicals produced by recombinant DNA technology
Flodh H, Johansson H-E, Jonsson M, Ekvarn S (1982) General toxicity in rats of biosynthetic and pituitary human growth hormone. Proceedings of the FDA-USP workshop on drug and reference standards for insulins, somatotropins and thyroid-axis hormones. United States Pharmacopeial Convention
Food and Drug Administration. Summary basis of approval NDA 19-107. Protropin
Food and Drug Administration. Summary basis of approval NDA 18-781. Human Insulin
Inveresk Research International (1985) Biotechnology products for human use - safety testing. Regulatory Affairs Bulletin 21:9–14
Jones AJS, O’Connor JV (1982) Chemical characterization of methionyl human growth hormone. Proceedings of the FDA-USP workshop on drug and reference standards for insulins, somatotropins and thyroid-axis hormones. United States Pharmacopeial Convention
National Institute for Biological Standards and Control (1986) Consideration for the standardization and control of the new generation of biological products (Draft)
Office of Biologies Research and Review Center for Drugs and Biologies, Food and Drug Administration (1984) Points to consider in the manufacture of injectable monoclonal antibody products intended for human use in vivo (draft, November 1984)
Office of Biologies Research and Review Center for Drugs and Biologies, Food and Drug Administration (1985) Points to consider in the production and testing of new drugs and biologies produced by recombinant DNA technology
Parish WE (1986) Predictive tests for occupational allergies. Arch Toxicol Suppl II:177–181
Petricciani JC (1983) An overview of safety and regulatory aspects of the new biotechnology. Regul Toxicol Pharmacol 3:428–433
United States Department of Agriculture (1984) New biotechnology for preparation of animal biological products. (Veterinary Services Memorandum No 800.68)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag
About this paper
Cite this paper
Wilson, A.B. (1987). The Toxicology of the End Products From Biotechnology Processes. In: Chambers, C.M., Chambers, P.L., Davies, D.S. (eds) Mechanisms and Models in Toxicology. Archives of Toxicology, Supplement, vol 11. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72558-6_31
Download citation
DOI: https://doi.org/10.1007/978-3-642-72558-6_31
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-17614-5
Online ISBN: 978-3-642-72558-6
eBook Packages: Springer Book Archive